Stargardt Disease clinical trials at UC Health
2 research studies open to eligible people
open to eligible people ages 12-60
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 12 and 60 years old. Funding Source - FDA OOPD
open to eligible people ages 16 years and up
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.